1. Symptomatic Therapy of Dyspnea with Strong Opioids and Its Effect on Ventilation in Palliative Care Patients 
Katri Elina Clemens, MD, PhD, Eberhard Klaschik, MD, PhD 
Journal of Pain and Symptom Management 
Volume 33, Issue 4, Pages (April 2007)
DOI: /j.jpainsymman
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
Intensity of dyspnea (NRS 0–10) at rest and on exertion at admission, during O2 insufflation, and 120minutes after the first opioid administration. (A) P=0.046; (B) P=0.025; (C) P=0.007; (D) P=0.003 compared with their respective baseline values at admission.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2
Changes in (f), O2 saturation (SaO2) of tcPCO2, and PF in individuals (1–11) including diagnosis and as mean in all patients (12). ∗Premedication with morphine, ∗∗premedication with fentanyl TTS. 1=at admission, 2=O2 insufflation, 3=30, 4=60, 5=90, 6=120minutes after opioid application. # P values (f) P2=0.046; P4=0.003; P6= (SaO2) P2=1.0; P4=0.017; P6= (tcPCO2) P2=0.286; P4=0.110; P6= (PF) P2=0.075; P4=0.062; P6=0.477.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Intensity of anxiety (NRS 0–10) at admission, during O2 insufflation, and 120minutes after the first opioid administration. P values compared with their respective baseline values. (A) P=0.15; (B) P=0.003.
Journal of Pain and Symptom Management  , DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions